<SEC-DOCUMENT>0000950170-23-062045.txt : 20231109
<SEC-HEADER>0000950170-23-062045.hdr.sgml : 20231109
<ACCEPTANCE-DATETIME>20231109161014
ACCESSION NUMBER:		0000950170-23-062045
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231109
DATE AS OF CHANGE:		20231109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Athira Pharma, Inc.
		CENTRAL INDEX KEY:			0001620463
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				453368487
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39503
		FILM NUMBER:		231392459

	BUSINESS ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011
		BUSINESS PHONE:		(425) 620-8501

	MAIL ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M3 Biotechnology, Inc.
		DATE OF NAME CHANGE:	20140924
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>atha-20231109.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-11-09T14:14:44.7521+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:atha="http://athira.com/20231109" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_f67e96aa-6f49-406a-bb43-185d146dfa7b" name="dei:EntityCentralIndexKey" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d">0001620463</ix:nonNumeric><ix:nonNumeric id="F_ce7a66d1-e147-4af3-a906-637d8f967f72" name="dei:AmendmentFlag" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="atha-20231109.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-09</xbrli:startDate><xbrli:endDate>2023-11-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Wingdings',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="agm_results"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, DC 20549</span></p>
  <p style="margin-left:33.333%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca30ccdd-7b55-4454-a352-fbb6927cde9a" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c55c79b6-cadf-439a-9491-a8e8989a8f74" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 9, 2023</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b95255b-c290-438c-a7ea-74acef1a3f25" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Athira Pharma, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:33.333%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.34%;"></td>
    <td style="width:33.34%;"></td>
    <td style="width:33.32%;"></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5551dd53-face-40ff-a168-cae771bdbac3" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63309a30-bf03-4b50-942a-919f912fca1c" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-39503</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9250d714-622c-4382-8dde-a5f7e22cb8e1" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45-3368487</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:20.15pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(State or other jurisdiction</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">of incorporation)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Commission</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">File Number)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(IRS Employer</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81211c85-9921-410c-ac50-0fa615a00776" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18706 North Creek Parkway</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e675702-2c2a-4163-be66-61f2572bfd20" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suite 104</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br /></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e63081a-a06b-4017-8bd2-3e8cacd24440" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bothell</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7715a73-7e29-4bba-afbb-8a178d0fa713" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e26d755-40a4-4a80-bb08-2a09a1e13944" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98011</span></ix:nonNumeric></span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices, including zip code)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ff830fb-d9f0-4cb2-88f6-e9494d699f6f" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">425</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d5b546e-770f-49b4-a65f-627adedd11d3" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">620-8501</span></ix:nonNumeric></span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#x2019;s telephone number, including area code)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former name or former address, if changed since last report)</span></p>
  <p style="margin-left:33.333%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:3.016%;"></td>
    <td style="width:96.984%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a3cab45-7472-48da-acdc-84f0196ab974" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45163998-088e-4ab4-8930-194699cdc042" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a45b0aff-983c-4d7b-b485-0e7e47582ec6" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1000c8e-90b8-4950-8cd2-0e3009150422" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35%;"></td>
    <td style="width:30%;"></td>
    <td style="width:35%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Title of each class</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_050ff7f0-6b2b-4829-9c0f-12b7398682fa" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_034cb865-960d-4f0c-a649-63fd7b252fd6" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ATHA</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad280bd5-f53c-477c-bf84-e5ecde8666f5" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;<br />(The Nasdaq Global Select Market)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25%;"></td>
    <td style="width:75%;"></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4697f79d-3bb4-48fe-94f4-b4f48a7a422e" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act).  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a54c22cb-b7d8-46ff-8e3d-eb907c2d0542" contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:'Wingdings',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 9, 2023, Athira Pharma, Inc. (the &#x201c;Company&#x201d;) issued a press release reporting its financial results for the quarter ended September 30, 2023. A copy of the press release is furnished herewith as Exhibit 99.1.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tem 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company&#x2019;s website (www.athira.com), its investor relations website (investors.athira.com), and its news site (investors.athira.com/news-and-events/press-releases). The Company uses these channels, as well as social media, including its X account (formerly known as Twitter)(@athirapharma), LinkedIn account (www.linkedin.com/company/athirapharma), Instagram account (@athirapharma) and Facebook page (www.facebook.com/athirapharmainc), to communicate with investors and the public about the Company, its product candidates, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;"></td>
    <td style="width:1%;"></td>
    <td style="width:90%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.028in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.028in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99.1</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="atha-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Athira Pharma, Inc. press release dated November 9, 2023</span></a></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information furnished in this Current Report under Items 2.02 and 7.01 and the exhibit attached hereto shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;"></td>
    <td style="width:45%;"></td>
    <td style="width:5%;"></td>
    <td style="width:45%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Athira Pharma, Inc.</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.042in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date:</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 9, 2023</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By:</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Mark Litton</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mark Litton</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>atha-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img247042425_0.jpg" alt="img247042425_0.jpg" style="width:174px;height:86px;">&#160;</p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Continues to report clinical and preclinical findings supporting the potential benefits of its small molecule therapeutic candidates targeting the neurotrophic HGF system as potential novel treatments for neurodegenerative diseases</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Expects to complete enrollment of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer&#x2019;s disease patients by the first quarter of 2024 with topline data expected in second half 2024</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Maintains strong balance sheet to support innovative clinical development pipeline through key inflection points</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">BOTHELL, Wash., November 9, 2023 -- </font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira Pharma, Inc.</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2023, and provided pipeline and business updates.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We enter the balance of the year more encouraged than ever by our increasing understanding of the power of modulating the neurotrophic HGF system as a potential strategy for treating a wide range of neurodegenerative diseases.  Our pipeline of small molecule HGF system modulators has the potential to become the basis of a future product line of neurodegenerative disease treatments,&#x201d; said Mark Litton, Ph.D., President and Chief Executive Officer of Athira. &#x201c;During the third quarter and recent weeks, we continued to present new data at key medical meetings that provide further evidence supporting the promise of both our fosgonimeton and ATH-1105 programs, and neurotrophic HGF system modulation in general, to modify the disease course for patients across a broad range of neurodegenerative diseases, including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). We believe we have a leading position in understanding the neurotrophic HGF system biology.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We remain keenly focused on advancing the ongoing Phase 2/3 LIFT-AD study, where we have added clinical sites and continued to engage with investigators to ensure completion of enrollment of this important study by the first quarter of 2024. This summer, we had a productive end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) which enabled alignment with the FDA on important aspects of the fosgonimeton program. We look forward to continued communication with the FDA, including discussions regarding our biomarker strategy and the LIFT-AD topline results, which are expected in the second half of 2024,&#x201d; concluded Dr. Litton.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Clinical Development &amp; Pipeline Programs</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira&#x2019;s drug development pipeline consists of potential first-in-class (fosgonimeton) and next-generation (ATH-1105 and ATH-1020) small molecule therapeutic candidates designed to promote the neurotrophic HGF system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system. Athira&#x2019;s therapeutic candidates have distinct properties which the Company believes may be applicable to a range of neurodegenerative diseases.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Fosgonimeton (ATH-1017)</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; A potentially first-in-class, once daily, subcutaneously administered drug candidate initially targeted to the potential treatment of Alzheimer&#x2019;s.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">LIFT-AD Phase 2/3 trial of fosgonimeton in mild-to-moderate Alzheimer&#x2019;s disease (</font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">NCT04488419</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">)</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In September 2022, an independent, unblinded interim efficacy and futility analysis was performed on 100 patients without concomitant acetylcholinesterase inhibitors (AChEIs) who completed the LIFT-AD Phase 2/3 trial. The positive outcome from the independent data monitoring committee supports the potential clinically meaningful activity of fosgonimeton and its potential to achieve the primary endpoint of the trial.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">LIFT-AD&#x2019;s primary endpoint is the Global Statistical Test (GST), a composite of the co-key secondary endpoints ADAS-Cog11 and ADCS-ADL23. The Company expects the GST endpoint to increase the understanding of the clinical impact of fosgonimeton, while elucidating the key drivers of potential treatment effect.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Key secondary and exploratory endpoints include changes in plasma biomarkers of neurodegeneration, protein pathology, and neuroinflammation.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In a protocol amendment submitted to FDA in May 2023, the LIFT-AD trial was modified to focus prospectively only on 40 mg dosing and to use this dose group compared to placebo for the primary analysis of results.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company expects to complete patient enrollment by the first quarter of 2024 and to report topline LIFT-AD results in the second half of 2024.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Based on interactions with the FDA, the Company believes that all registrational pathways remain viable and contingent on LIFT-AD results. The FDA is open to ongoing dialogue with the Company regarding the LIFT-AD trial once completed as well as other aspects of our program to develop fosgonimeton as a potential treatment for mild-to-moderate AD.</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Open Label Extension (OLEX) fosgonimeton trial (</font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">NCT04886063</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">)</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Eligible participants who completed the LIFT-AD or ACT-AD trials and elect to participate in the ongoing OLEX are able to receive up to 30 months of open-label treatment. </font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company believes OLEX will complement the Company&#x2019;s long-term safety database and provide insights into fosgonimeton&#x2019;s long-term effects for up to three years.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">OLEX continues to enroll with greater than 85% of participants who completed either study having elected to enroll in the OLEX study.</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ATH-1105</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; A next-generation, orally administered drug candidate developed for the potential treatment of amyotrophic lateral sclerosis (ALS) as the Company&#x2019;s initial indication.</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ATH-1105 is supported by preclinical findings that demonstrated statistically significant improvements on nerve and motor function, biomarkers of inflammation and neurodegeneration, and survival in various ALS animal models.</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">IND-enabling studies will continue through the remainder of 2023 in order to support the potential initiation of first-in-human studies in the first half of 2024 to evaluate this promising drug candidate as a treatment for ALS.</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Recent and Upcoming Presentations</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira continues to expand the body of clinical and preclinical findings supporting the potential benefits of its pipeline of small molecule therapeutic candidates targeting the neurotrophic HGF system to deliver novel treatments for neurodegenerative diseases.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">    </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company </font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">presented</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> new data at the Alzheimer&#x2019;s Association International Conference 2023 (AAIC) that included:</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">A post-hoc analysis of the Phase 2 ACT-AD study and data from the OLEX study in subjects with mild-to-moderate AD. The data suggested that improvements in plasma biomarkers of neurodegeneration (NfL) and neuroinflammation (glial fibrillary acidic protein, or GFAP) significantly correlate with GST, a composite score of cognition and function, further supporting the potential clinical utility of these biomarkers.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Preclinical data demonstrating that fosgonimeton attenuates amyloid-&#x3b2;-mediated toxicity in vitro and highlighting its potential as a therapeutic candidate to slow disease progression and restore neuronal health.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Preclinical data demonstrating that ATH-1105 offers protection against several pathologies common to ALS and frontotemporal dementia and supporting its therapeutic potential for the treatment of these indications.</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company presented preclinical data that further supports the potential of fosgonimeton to treat neurodegenerative diseases such as AD at the 16</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> Annual Clinical Trials on Alzheimer&#x2019;s Disease conference (CTAD). The data presented:</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Demonstrated the ability of fosgonimeton to counteract mechanisms of amyloid-&#x3b2; (A&#x3b2;)-induced toxicity, reduce tau pathology, and promote neuronal survival in vitro.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Showed treatment with fosgonimeton leads to improved cognitive performance in an A&#x3b2;-driven rat model of AD, suggesting that the in vitro activity of fosgonimeton A&#x3b2;-toxicity translates to functional benefits in vivo.</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company </font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">presented</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> preclinical data demonstrating the neuroprotective properties of ATH-1105 in several preclinical models of ALS at the 22nd Annual Northeast ALS Consortium (NEALS) Meeting that demonstrated:</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In vitro, ATH-1105 protected motor neurons from excitotoxicity, reduced TDP-43 mis-localization, preserved metabolic stability, and maintained neuromuscular junction integrity.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In vivo, treatment with ATH-1105 improved motor and nerve function, mitigated inflammation and neurodegeneration, and reduced plasma NfL and pTDP-43 accumulation in ALS mice when administered alone or in combination with riluzole. </font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira will be presenting new preclinical data supporting the potential therapeutic benefit of fosgonimeton for the treatment of Alzheimer&#x2019;s disease at Neuroscience 2023. The event is hosted by the Society for Neuroscience and will take place at the Walter E. Washington Convention Center in Washington, D.C., November 11-15, 2023.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Presentation Details:</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Title:</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> Fosgonimeton, a small-molecule positive modulator of the neurotrophic HGF system, protects against amyloid beta-induced pathological alterations in Alzheimer's disease models in vitro and in vivo</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Format:</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> Oral Nanosymposium</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Session:</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> NAN076<br>Development of Novel Therapies for Neurodegenerative and Neuromuscular Diseases</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Presenter:</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> Sharay Setti, PhD, Senior Scientist, Athira Pharma</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Time/Date: </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Wednesday, November 15, Session time: 8:00 a.m. &#x2013; 12:00 p.m. Eastern Time, Presentation time: 8:15 a.m. &#x2013; 8:30 am. Eastern Time</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Title: </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Fosgonimeton, a small-molecule positive modulator of the neurotrophic hepatocyte growth factor system, inhibits LPS-mediated neuroinflammation in BV2 microglia</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Format:</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> Poster</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Session:</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PSTR 203.06. Neuroinflammation: Microglia</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Presenter: </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Wei Wu, PhD, Senior Scientist II, Athira Pharma</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Time/Date: </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Monday, November 13, Session time: 8:00 a.m. &#x2013; 12:00 p.m. Eastern Time, Presentation time: 9:00 a.m. &#x2013; 10:00 a.m. Eastern Time</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Financial Results</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cash Position. </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cash, cash equivalents and investments were $172.9 million as of September 30, 2023, compared with $245.2 million as of December 31, 2022. Net cash used in operations was $74.5 million for the nine months ended September 30, 2023, compared with $56.8 million for the nine months ended September 30, 2022.<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Research and Development (R&amp;D) Expenses. </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">R&amp;D expenses were $27.2 million for the quarter ended September 30, 2023, compared with $17.0 million for the quarter ended September 30, 2022. The increase was driven primarily by costs related to increased clinical trial activities, manufacturing activities and personnel expense.<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">General and Administrative (G&amp;A) Expenses. </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">G&amp;A expenses were $7.8 million for the quarter ended September 30, 2023, compared with $7.2 million for the quarter ended September 30, 2022. The increase was primarily due to increases in personnel expenses, partially offset by a decrease in business development expenses.<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Net Loss. </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss was $32.7 million, or $0.87 per share, for the quarter ended September 30, 2023, compared with a net loss of $20.2 million, or $0.53 per share, for the quarter ended September 30, 2022.</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Athira Pharma, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">therapeutic candidates that modulate the neurotrophic HGF system. For more information, visit </font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">w</font><font style="white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ww.athira.com</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. You can also follow Athira on </font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Facebook</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, </font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, </font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">X</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> (formerly known as Twitter) and </font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Instagram</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This communication contains &#x201c;forward-looking statements&#x201d; within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: product candidates as a potential treatment for neurodegenerative diseases such as Alzheimer&#x2019;s disease and amyotrophic lateral sclerosis; Athira&#x2019;s platform technology and potential therapies; future development plans; expectations regarding the potential efficacy and commercial potential of Athira&#x2019;s product candidates; the anticipated reporting of data; the impact of Athira&#x2019;s July 2023 End of Phase 2 Meeting with the U.S. Food and Drug Administration on its future development plans and pipeline candidates; and Athira&#x2019;s ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;on track,&#x201d; &#x201c;would,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;believe,&#x201d; &#x201c;intend,&#x201d; &#x201c;pursue,&#x201d; &#x201c;continue,&#x201d; &#x201c;suggest,&#x201d; &#x201c;potential,&#x201d; and similar expressions. Any forward-looking statements are based on management&#x2019;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data from preclinical and clinical trials may not support the safety, efficacy and tolerability of Athira&#x2019;s product candidates; development of product candidates may cease or be delayed; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for product candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; Athira may not be able to recruit sufficient patients for its clinical trials; the outcome of legal proceedings that have been or may in the future be instituted against Athira, its directors and officers; possible negative interactions of Athira's product candidates with other treatments; Athira&#x2019;s assumptions regarding the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira&#x2019;s clinical development plans as a result of pandemics or health epidemics, which could further delay development timelines; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira&#x2019;s filings with the Securities and Exchange Commission from time to time. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investor &amp; Media Contact</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br>Julie Rathbun<br>Athira Pharma<br></font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Julie.rathbun@athira.com</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> <br>206-769-9219</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Condensed Consolidated Balance Sheets</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">(Amounts in thousands)</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.82%;"></td>
    <td style="width:1.46%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:12.6%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.48%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:12.6%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:11pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">September 30,</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">December 31,</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">2023</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">2022</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">(unaudited)</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Assets</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Cash and cash equivalents</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">110,334</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">95,966</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Short-term investments</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">62,614</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">104,378</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Other short-term assets</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">5,556</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">7,189</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Long-term investments</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;&#x2014;</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">44,829</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Other long-term assets</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">6,196</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">5,791</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Total assets</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">184,700</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">258,153</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Liabilities and stockholders' equity</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Current liabilities</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">28,622</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">21,431</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Long-term liabilities</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">1,314</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">1,585</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">29,936</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">23,016</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Stockholders' equity</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">154,764</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">235,137</font></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Total liabilities and stockholders' equity</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">184,700</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">258,153</font></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:1pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">(Amounts in thousands, except share and per share amounts)</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">(Unaudited)</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.129%;"></td>
    <td style="width:4.679%;"></td>
    <td style="width:18.696%;"></td>
    <td style="width:2.799%;"></td>
    <td style="width:18.696%;"></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">Three Months Ended <br>September 30,</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">2023</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">2022</font></p></td>
   </tr>
   <tr style="height:12.95pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.95pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;$            27,202</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;$            16,965</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">General and administrative</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;7,840</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;7,168</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:40pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:40pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;35,042</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;24,133</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;(35,042)</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;(24,133)</font></p></td>
   </tr>
   <tr style="height:12.95pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Grant income</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;&#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;2,959</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Other income, net</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;2,072</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;985</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Net loss</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;$         (32,970)</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;$         (20,189)</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Unrealized gain (loss) on available-for-sale securities</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;261</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;(547)</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Comprehensive loss attributable to common stockholders</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;$         (32,709)</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;$         (20,736)</font></p></td>
   </tr>
   <tr style="height:27.35pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Net loss per share attributable to common stockholders,<br>&#160;&#160;&#160;basic and diluted</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;$             (0.87)</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;$             (0.53)</font></p></td>
   </tr>
   <tr style="height:39.6pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">Weighted-average shares used in computing net loss per<br>&#160;&#160;&#160;share attributable to common stockholders, basic<br>&#160;&#160;&#160;and diluted</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;38,054,583</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;&#160;37,817,724</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img247042425_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img247042425_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %8 K4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5CY5R#&Z^O''ZU[?7+4AR2L;0E=!1116904444 %%%% !1110 4444 %%%%
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M -]OY5Z/7G'Q9_X]-/\ ]]OY5I2^-$3^%GEM%%%=YSGM_P .O^1,M/\ >?\
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MPKSSQ6NW7I/=%->AUP7C%-NLJW]Z,5YV:*]#YGHY6[5_D0>%6V^(8!ZJX_\
M'37HE>:>'W\O7K,^K[?S&*]+J<J?[EKS_P B\V7[Y/R_S"BBBO3/+"BBB@ H
M-%9NOZDNDZ%=WK$ QQG;[L>!^M-*[L!Y'XUOGU[QDUM 2X1A;Q >N>?UKV/2
M[%-,TNVLHP-L,87CN>]>2?#G36U/Q0U],"RVP,I)[N>G]3^%>S5M6=K170SA
MW"O-_BKI6^VM-41>8SY4A'H>E>D5F:_IJZMH5W9$9,D9V^S#D?K6<)<LDRI*
MZL?/-%*R-&[(P(9200>QI*] YCT_X5:MNAN])D;E#YT7T/##^5>E5\_>%M4.
MD>)+.ZSA-^Q_]T\&OH!2&4,#D$9!KBKQM*_<WINZ%HHHK$T&R?ZM_H:^:YO^
M/B7_ 'V_F:^E)/\ 5O\ 0U\US?\ 'Q+_ +[?S-=.'ZF57H,KHO T4<_C"RCE
MC21#NRKJ"#\I[&N=KI? /_(Z6/\ P+_T$UT3^%F4=T>T?V3IO_0/M/\ ORO^
M%']DZ;_T#[3_ +\K_A5RBO/NSJL5$TO3XW#I8VRLIR&6%00?RJW112 *\X^+
M/_'II_\ OM_*O1Z\X^+/_'II_P#OM_*M*7QHB?PGEM%%%=YSF[X8T6;Q)K,%
MD[M]GB7<Y_NIGH/J:]UL[.WL+6.UMHECAC&U54=*X;X56"Q:-=7Y'SSR[ ?]
ME?\ ZY->@5Q5I7E;L=%-65PI#2T5B6>/_$G0(]-U*/4+9 D5UG>JC@/_ /7K
MAJ]H^)ENLOA)Y".8I48?B<?UKQ>NZC*\3GFK,EM;F:RNHKF!RDL3!E(]17T)
MHFI)K&C6E^G2:,$CT/0C\\U\[5Z[\*KHR^'[FV))\B<X]@PS_2HQ$?=N.F];
M'>5D^)_^18U+_KW?^5:U9/B?_D6-2_Z]W_E7+'=&SV/GSM11VHKTCE._^%/_
M "&KS_KB/YUZU7DOPI_Y#5Y_UQ'\Z]:KAK_&=%/X0KRGXG:^\UZFC0.1%$ \
M^#U8]!^ _G7JQX&:^<]8NFOM:O;ICDRS,WX9XJJ$;RN*H[*Q2JWI=DVHZK:V
M:]9I%3\S52ND\!1B7QI8 @<%F_)2:ZI.R;,5JSV^TM8K*TBMH5"QQ*%4#T%3
M445YQU!7 ?$CPXVH6L.H6=NTEU&=CK&N2RG_  KOZ*J,G%W0FKJQ@>#;F\N/
M#5LM_%+'<PCRF$@P3CH?RKG?B?K$MO90:7;[\W'S2[1_".WXFO0:C>&*1LO$
MC'U*@TU)*7-836ECDO ?A>'1]+CO9XP;^X7<68<QJ>BCT]Z[&D P,4M3*3D[
ML:5E8****0R"\L[>_M);6ZB62&1=K*PZUX#XATAM"UNXL6)*(<QL>ZGI7T+7
ME/Q7M534;&Z P7C*$^N#6]"5I6,ZBTN>>5T7@SQ!)H.MQDN?LLY"3+GCV/X5
MSM%=;2:LS%.VI], AE!!R",BEK'\+7AO_#&G7+'+-" 3ZD<'^5;%><U9V.I:
MA1112 **** "BBB@ HHHH **** "BBD)P,F@#.U+1+/4T/FQ[9.TB\$?XUPV
MKZ)<:2X\PJ\3'Y7'?\*ZK5_%-O9!HK7$T_3C[J_6N)N[VXOIS-<2%V/KT'TK
MPLQGAV[15Y>7ZGNY=#$)7D[1[/\ 0@I>U36MK/>3"&WB:1SV':DN;::TF,4\
M;1N.QKR^5VYK:'J\T;\M]3I/#&AVUR!>7#I*5/RQ ]#ZFNS P,#I7E-I>7%C
M,)K>5D<>G0_6NXT;Q-!J&V&XQ#<=/]EOI7M9=B:*C[.UG^9XF8X:LY>TO=?D
M;]%%%>N>0%%%% !7%^-DQ=VLGJA7]:[2N5\;1YM+67^ZY!_$5Q9A&^'E_74[
M<OE;$1.5TZ3RM3M9/[LJG]:]4KR-&VR*WH0:]9A?S((W_O*#^E<F42TG'T.S
M-XZPEZCZ***]@\8**** "O-OBMJVV"TTJ-N7/G2@>@X KTAB%4D]!S7AFK2R
M>*O'+1QDLLLXA3V0=_YFMJ*O*[Z$5'I8]$^'.E?V?X:6=UQ+=-YA^G:NPJ*W
MA2VMHX(QA(U"@>PJ6LY/F=RDK*P4445(SPSQ[I7]E^*K@HN(;G]\GX_>'Y_S
MKF:]=^*&E?:=$BOT7+VS_-_NFO(J[Z4N:*.>:LP^E>\^#-5_M;PQ:S%LR1KY
M<GU%>#5Z#\+-6\G4;G2Y&^6=?,CS_>'7]*FO&\;CINS/6****XC<;)_JW^AK
MYKF_X^)?]]OYFOI23_5O]#7S7-_Q\2_[[?S-=.'ZF57H,KI? /\ R.EC_P "
M_P#037-5TO@'_D=+'_@7_H)K>?PLSCNCW2BBBO/.D**** "O./BS_P >FG_[
M[?RKT>O./BS_ ,>FG_[[?RK2E\:(G\+/+:***[SG/;?ARH7P9:X'5W)_[Z-=
M97*_#K_D3+3_ 'G_ /0C755Y]3XF=,=D%%%%04<K\1?^1+O/]Y/_ $(5XA7M
M_P 1?^1+O/\ >3_T(5XA79A_A,*FX5Z?\)"?L^J#MO3^1KS"O3_A)_J-3_WT
M_D:JM\#%#XCTJLGQ/_R+&I?]>[_RK6K)\3_\BQJ7_7N_\JXH[HW>Q\^=J*.U
M%>D<IW_PI_Y#5Y_UQ'\Z]:KR7X4_\AJ\_P"N(_G7K5<-?XSHI_"1SG$$A'7:
M?Y5\VR_ZZ3_>/\Z^DI_^/>7_ '#_ "KYME_UTG^\?YUIA^I-7H,KI_A[_P C
MM8_23_T US%=/\/?^1VL?I)_Z :WG\+,X[H]RHHHKSSI"BBB@ HHK)USQ%I_
MA^V\V]EPQ^Y&O+-]!32;T0;&M2$@<DX%>/:M\3=6O'9;!$LX>Q^\Y_'H*YBY
MUW5KMBT^HW+YZCS#C\JV5"3W,W41]#>;'_ST3\Z4.K?=8'Z&O M.T+7]7'F6
MEO<R(?XRQ _,FM4>$O&5D \*3@C_ )Y3\_SH=%+[0<[['M5>;?%H#[/IK=][
MC]!6/8^./$7A^Z6#5X9)X@>4F7:^/9N]6?B#K-GKFC:5>64FY"[AE/53@<$4
MX4W&:%*2<6>?4445UF)[C\/6+>"K$$]-X'_?1KJ*Y;X=_P#(EV7U?_T(UU->
M=/XF=4=D%%%%2,**** "BBB@ HHHH *,UFW^N6&G*?.F!D[1IRU<GJ/BR\N\
MQVX^SQGN.6/XUR5\;2HZ-W?8ZZ&"JUM4K+NSK=1UNRTU#YTF9.T:<L:XO5/$
MEYJ)**?(@/\  IY/U-9#,78LS%F/4DYJQ9:?=:A+Y=M$7]6[#ZFO&K8VMB'R
M1T79'LT,#1PZYY:ONRK6UI/ARZU(B20&&W_OL.6^@KHM*\*V]GMENB)YO3'R
MBNA    & .U=.&RQOWJWW'-B<S7PT?O*MAIMMIT(CMXPOJW<_6B_TVUU&$QW
M$8;T8=1]#5NBO8]G#EY+:'C^TGS<]]3SG6/#USIC&109;?LX'(^M8XZY%>NL
MH92K $'@@UR>M>% ^ZXTY<-U:'U^E>-BLM<??I;=CVL)F2E[E;?N5-$\4R6I
M6WOB7AZ"3J5^OJ*[6*:.:-9(G#HPR&!R#7DS*R.4=2K X((P16EI&N7&DR@*
M2\!/S1D_RJ,)F#I^Y5V_(K%Y=&I[]+1_F>E455L;^WU&V6>W<,IZCNI]#5JO
M>C)25UL>#*+B[/<*PO%T/F:"[?\ /-U;^G]:W:HZS#Y^CW<>,YC)'U'-98B/
M/2E'R-</+DJQEYH\OKU#1I?.T>U?/6,"O+Z] \)3>;HBIGF-RM>+E4K57'NC
MVLUC>DI=F;U%%%?0'SX4444 8'C'51I/AB[G!Q(Z^7'_ +QXKQC0X]8;4!+H
MT4SW2 _/&N2N>_M78?%35O.O[72XVRL*^;(!_>/ 'Y?SKL_!&D+I/AFV0H!-
M,/,D..2371%^SIW[F37-*QPOV/XBM\VZ[Y_Z:+_C2&?XB6/+)>N!VVAQ^E>O
M45/M?)%<GF>20_$;Q%I[[=1L4D /.^,QFNGTGXEZ-J!6.Z#V4I_YZ<I_WT/Z
MUU\]M!<H4GACE7T=0:Y75_AUHNHJS6Z&SF/1HNGXBCFIRW5@M);,Z&\AM]9T
MB>!722*>,J&4Y'(XKYYN;=[2[FMI!AXG*,/<&NOGL_$W@"Y$L4AELB?O+EHV
M]B.QK \0ZC;ZOJK:A!$86G4&:/LK]#@]P>M;4H\NVJ,YN_J957=(OWTO6+6]
M0X,,@8^X[C\JI45LU<@^E8)DN((YHR"CJ&!]C4E<C\.]5_M'PS'$[9EM3Y3?
M3M^E==7G25G8Z4[JXV3_ %;_ $-?-<W_ !\2_P"^W\S7TI)_JW^AKYKF_P"/
MB7_?;^9KHP_4SJ]!E=+X!_Y'2Q_X%_Z":YJNE\ _\CI8_P# O_036\_A9G'=
M'NE%%%>>=(4444 %><?%G_CTT_\ WV_E7H]><?%G_CTT_P#WV_E6E+XT1/X6
M>6T445WG.>W_  Z_Y$RT_P!Y_P#T(UU5<K\.O^1,M/\ >?\ ]"-=57GU/B9T
MQV04445!1ROQ%_Y$N\_WD_\ 0A7B%>W_ !%_Y$N\_P!Y/_0A7B%=F'^$PJ;A
M7I_PD_U&I_[Z?R->85Z?\)/]1J?^^G\C55O@8H?$>E5D^)_^18U+_KW?^5:U
M9/B?_D6-2_Z]W_E7%'=&[V/GSM11VHKTCE._^%/_ "&KS_KB/YUZU7DOPI_Y
M#5Y_UQ'\Z]:KAK_&=%/X2.?_ (]Y?]P_RKYME_UTG^\?YU])3_\ 'O+_ +A_
ME7S;+_KI/]X_SK3#]2:O0973_#W_ )':Q^DG_H!KF*Z?X>_\CM8_23_T UO/
MX69QW1[E1117GG2%%%% %#6M5AT729[Z;D1KD+_>/85X#JFIW6L:A+>W<A>1
MST[*/0>U>C_%>]9+&QLU.!(Y=OP__77EE=="-E<PJ/6P5UG@+PY'KVKO)<KN
MM+4!G7^^QZ"N3KV+X76ZQ>%WF &Z:=B3].*NK+ECH*"NSM(XTB14C4*BC 4#
M %/Q117"=!GZMHUEK5F]M>PJZL.&Q\RGU!KP?6]*GT359].F8D1ME3V8'H:^
MB*\I^*]HJ:A8W8&"Z%#[XK>A)J7*9U%I<\\HHHKL,#W#X=_\B79?5_\ T(UU
M-<M\._\ D2[+ZO\ ^A&NIKSY_$SJCL@HHHJ!A117,^.]7ET?PU+) VV:8B)6
M],]?TIQ5W83=E<CUKQ_HVC3M;[VNIUX9(>0I]">E5-.^)FC7LRQ7"36A8X#2
M<K^)'2O&\DDDG)/4T&NOV$;&/M&?2Z.LB*Z,&5AD$'((KD_%VJ7-O/%:02-&
MA3<Q4\FLSX7:Q+=V%SILS%C:D-&3V4YX_,5UFL:'!JZH78QRIPKCT]#7F8ZE
M4=-PIO4[\%5IQJJ=1:'FY))))R3W-3VEC=7TFRVA:0]R!P/J:[*S\'V<#A[A
MVG(Z+T%=!#!%;QB.&-40= HQ7D4<KG+6H['K5LUA'2DKG+Z;X.1,27[[S_SS
M3I^)KJ(((K:(1PQJB#H%&*DHKUZ.'IT5:"/'K8BI6=YL****W,0HHHH ****
M ,76O#\&J(9$Q'<@</V/UK@;JTGLKAH+B,I(O;U]Q7K%9^JZ3;ZK;^7*,./N
MN.HKSL9@(U??AI+\STL'CY4O<GK'\CSS3M1N-,N1- V/[R]F%>AZ5JMOJML)
M(FPX^_&>JFO/-1TZXTRY,,ZX_NL.C#U%,LKV:PN5G@;:P_(CT->9AL5/#2Y)
M[=4>EBL+#$PYX;]&>K4V1=\;*>X(JAI&K0:M;>9&0)%^^G<&M$U]#"<9QYHZ
MIGSTX2A+EDK-'DUQ$8;F6(]4<C]:ZKP3/\MU 3T(8"L7Q%!]GURX&.&.X?C5
MCPG<>3KBH3Q*A7^M?.X;]UBDO.Q]'B?WV$;\KGH-%%%?2GS(4R:58(7E<X5%
M+$^PI]<G\0M5_LWPO*B-B6Y/E+ZX[_I3BKNPF[*YYO8H_BOQV&;)6:<R-[(/
M_K"O<U4*H51@ 8 KS7X4Z3B.[U:1>6/DQ$^G5C_*O2ZUK/WK+H336EPHHHK$
ML**** (YH8YX6BF17C8896&017D/CGP6-%<ZCIZDV+M\Z?\ /(_X5[%4%Y:Q
M7UI+:SJ&CE4JP/O5PFX.Y,HW1\VT5<U6Q?3-5N;*08:&0K]1VJG7>M3F.T^&
MFJ_8O$9LW;$=XFT?[XY']:]EKYKM;F2SNX;F,XDB<.I]P<U]%:=>1ZCIUO>1
MGY)D#C\:Y<1&SN;4WI8LL-RD>HQ7S7<J4NYU(P1(P/YFOI6O!/&>FMIGBJ]C
M*XCE?S8_<-S1AWJT%5:&#72^ ?\ D=+'_@7_ *":YJMCPK=K8^)]/G<@*)0I
M)[9XKIG\+,EN?0-%(#D9I:\XZ@HHKE/&'C#_ (1@VR1P+/++DE2V-H'>G&+D
M[(3=M6=77G'Q9_X]-/\ ]]OY5W6D7<U_I5M=SQ"*2:,.4!Z9KA?BS_QZ:?\
M[[?RK2E\:)G\)Y;1117<<Y[?\.O^1,M/]Y__ $(UU5<K\.O^1,M/]Y__ $(U
MU5>?4^)G3'9!1114%'*_$7_D2[S_ 'D_]"%>(5[?\1?^1+O/]Y/_ $(5XA79
MA_A,*FX5Z?\ "3_4:G_OI_(UYA7I_P )/]1J?^^G\C55O@8H?$>E5D^)_P#D
M6-2_Z]W_ )5K5D^)_P#D6-2_Z]W_ )5Q1W1N]CY\[44=J*](Y3O_ (4_\AJ\
M_P"N(_G7K5>2_"G_ )#5Y_UQ'\Z]:KAK_&=%/X2.?_CWE_W#_*OFV7_72?[Q
M_G7TE/\ \>\O^X?Y5\VR_P"ND_WC_.M,/U)J]!E=/\/?^1VL?I)_Z :YBNG^
M'O\ R.UC])/_ $ UO/X69QW1[E1117GG2%%%% 'EOQ94_:=-;G:5<?RKSBO9
M?B7I37WAX7,2[GM6WG']WO7C5=M%W@<]1>\%>T?#/_D3H_\ KM)_.O%Z]7^%
M-^LFE7=@6^>&7S /]EO_ *XHKKW!T_B/0J***XC<*\T^+3CRM-3^+<Y_05Z7
M7C?Q-U-+SQ"EK&V5M4VMC^\>36M%7F14?NG%4445W'.>X?#O_D2[+ZO_ .A&
MNIKEOAW_ ,B79?5__0C74UY\_B9U1V04445 PKE?B!I4NI^&)?)4M) PE"CN
M!UKJJ",C!IQ=G<35U8^9J*]DUKX:Z9J=P]Q:R/9RN<L$&4)]<=JJ:=\*["WF
M62^O)+E0<^6J[ ?K79[>%C'V<B'X5:7+!:7FI2*56XVQQ@]PN<G\S7HU1PP1
MVT*0PHJ1H,*JC  J2N2<N:5S:*LK!1114C"BBB@ HHHH **** "BBB@ HHHH
M IZCIT&IVQAG7/\ =;NI]17G6IZ9/I=T89AP>4?LPKU&J>I:;!J=HT$R^ZMW
M4^M<.,P:KKF7Q'=@\8Z$N67PGFMC>S:?=)<0-AEZCL1Z&O1]+U.'5+031'##
MAU[J:\ZU#3YM-NVMYQR/NMV8>HI^EZE-I=XL\1^7HZ=F%>3A,5+#3Y)[=?(]
M;%X6.)ASPWZ>9N>-+?;=V]P!PZE3]17/6-Q]EU"WGS_JY 3].]=AXB>+5/#:
MWD!W"-@_N.Q'ZUP]+'+DQ'/'K9H>!?/A^272Z9ZZI#*".A&12UG:'=?:]&MI
M"<MLVM]1Q6C7T<)*<5)=3YR<7"3B^@5XY\2=3;4?$D>GPG<EJH3 [NW7^@KV
M.N13X>Z6NLC4Y+FZEF\WS2'88)SGGBMJ4E%W9G--JR-KP[IJZ1H%G9@8*1@M
M[L>36I114-W=R@HHHI %%%% !1110!Y+\4M)^SZK;ZFB_)<KL<_[:]/S'\JX
M"OH77M"M?$.G?8KLNJ!@X9" P(],US'_  JK1O\ G[O?^^E_PKJIUDHV9C*#
M;NCR&O7OAAJOVK1)+!VR]J_RC_9-'_"JM&_Y^[W_ +Z7_"M;P_X*L?#E\UU:
M7-TS.FQED8%2/P%*I4A*-AQC),Z6N4\;>%?^$BL%DM\+>P F,G^(?W:ZNBN>
M+<7=&C5U8^:[FVGL[AX+F)XI4.&1Q@BH@2"""01R"*^A-8\.:7KL>V^M5=A]
MV0<.OT(KB[WX3Q%B;+474=EE3/ZBNN->+W,73:V+?A3X@V5Q916FK2B"YC&W
MS6^ZX]<]C77'7=*$>\ZC:[?7S17F3_"K5@V%N[5AZ\BB/X4ZJS?/=VJCU&36
M<HTV[IE)S70['5OB#H>G0MY-P+N;'RI%R,^YKA](L+_Q[XG.H7RD6:,"Y_A
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M9U(\LK%1=U<****@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:-G(%33MS78Y7MH<QX*\&P^)(KF>[DECAC(5#'CD]ZZS_A56C_\ /W=_F/\
M"NF\-Z,N@Z)!8@AG49D8?Q,>M:U5.K)RT8HP5M3SK4/A=81:?<26ES<M<(A9
M%8C!([=*X[P1JQT?Q/ 9#MBF/DR ^_\ ]>O=J\QU;X97=SK%S=6-U#%!)(9$
M1@<KGG'YU4*ETU-DRA9WB>FYSTI:K:?'<0Z?;Q73J\Z(%=EZ$CO5FN<U"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K+U^P_M#2I449D3YT^HK4HJ*D%.+B^I=.;A)270\AKO/!]ZUQIC6[Y
M+0-@'_9/2JU]X.6>\>6WN!'&YW%"N<'VK<TK2H-)M?)B)9F.7<]6->3@L)6H
MUKRV_,];&XNC6HVCO^1?HHHKV3Q@HHHH **** "BBB@ HHHH **** "BBB@
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MH\[_ )Z.=S#Z>E;=35J\^B"$+:L****Q- HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>atha-20231109_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-09T14:14:44.7914+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="atha-20231109.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>atha-20231109_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-09T14:14:44.9904+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>atha-20231109.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-09T14:14:44.8328+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://athira.com/20231109" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:atha="http://athira.com/20231109" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atha-20231109_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atha-20231109_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139880448726144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  09,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Athira Pharma, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001620463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-39503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-3368487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">18706 North Creek Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bothell<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">620-8501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATHA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>atha-20231109_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atha-20231109.xsd" xlink:type="simple"/>
    <context id="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <startDate>2023-11-09</startDate>
            <endDate>2023-11-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_f67e96aa-6f49-406a-bb43-185d146dfa7b">0001620463</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_ce7a66d1-e147-4af3-a906-637d8f967f72">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_ca30ccdd-7b55-4454-a352-fbb6927cde9a">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_c55c79b6-cadf-439a-9491-a8e8989a8f74">2023-11-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_4b95255b-c290-438c-a7ea-74acef1a3f25">Athira Pharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_5551dd53-face-40ff-a168-cae771bdbac3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_63309a30-bf03-4b50-942a-919f912fca1c">001-39503</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_9250d714-622c-4382-8dde-a5f7e22cb8e1">45-3368487</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_81211c85-9921-410c-ac50-0fa615a00776">18706 North Creek Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_2e675702-2c2a-4163-be66-61f2572bfd20">Suite 104</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_4e63081a-a06b-4017-8bd2-3e8cacd24440">Bothell</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_d7715a73-7e29-4bba-afbb-8a178d0fa713">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_0e26d755-40a4-4a80-bb08-2a09a1e13944">98011</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_0ff830fb-d9f0-4cb2-88f6-e9494d699f6f">425</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_8d5b546e-770f-49b4-a65f-627adedd11d3">620-8501</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_2a3cab45-7472-48da-acdc-84f0196ab974">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_45163998-088e-4ab4-8930-194699cdc042">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_a45b0aff-983c-4d7b-b485-0e7e47582ec6">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_d1000c8e-90b8-4950-8cd2-0e3009150422">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_050ff7f0-6b2b-4829-9c0f-12b7398682fa">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_034cb865-960d-4f0c-a649-63fd7b252fd6">ATHA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_ad280bd5-f53c-477c-bf84-e5ecde8666f5">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_4697f79d-3bb4-48fe-94f4-b4f48a7a422e">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d"
      id="F_a54c22cb-b7d8-46ff-8e3d-eb907c2d0542">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !&@6E7'#AEZC\!   \ @  #P
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M=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ 1H%I5R0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( $:!:5=ED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !&@6E7G"AH\^T    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !&@6E7
MF5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( $:!:5==O"CTCP0  -P1   8              "
M@0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !&@6E7
MGZ ;\+$"  #B#   #0              @ '1#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( $:!:5>7BKL<P    !,"   +              "  :T/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( $:!:5<<.&7J/P$  #P"   /
M      "  980  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !&@6E7)!Z;
MHJT   #X 0  &@              @ $"$@  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !&@6E799!YDAD!  #/ P  $P
M    @ 'G$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   Q
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="atha-20231109.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="atha-20231109.htm">atha-20231109.htm</File>
    <File>atha-20231109.xsd</File>
    <File>atha-20231109_lab.xml</File>
    <File>atha-20231109_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "atha-20231109.htm": {
   "nsprefix": "atha",
   "nsuri": "http://athira.com/20231109",
   "dts": {
    "inline": {
     "local": [
      "atha-20231109.htm"
     ]
    },
    "schema": {
     "local": [
      "atha-20231109.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "atha-20231109_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atha-20231109_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231109.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b7110cf0-3960-486d-b89a-09c8cc8b9a3d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231109.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://athira.com/20231109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-23-062045-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-062045-xbrl.zip
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MIF6:<>#B,+1,[("VC$D,9IV1$,]TB6'XOK<<K7J?4L&DK'Y]XAFHZXW0J,W
M-SQ <5'TU1X:=H5.B;BZ(>,%"G8#AK[]2N%:BWF^ZQL6MF*P[AW3LW'$/ ][
M9F*YOA4EU#)>"RNL9F#%^0@Z0J;A-!\+=B.!NO<.Z.68X##/-@*38&)X$78,
MT\=!1"ULLR F,;4<QUDN)AS GU_$17[3$)_C+\H,2]/F8\%K\0+J^R (?!O[
MS JQ$T6 "TD4X8"8?D!!3OCFDES4%09H _B+.!7Y-5?[U!H!W=_WFX\!KX0
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M\-/IM"ZZ0><7W^_Y_MYE/-T(LEAFZ%WT'JFK8&S&,*4;=$M8R"(24C31@WY
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M<$#F_./J;->@?JG_:KWZ"U!+ P04    " !&@6E7#:UW(NLF  !U00( #P
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M!SD,E,?$M2\P70"<)FC=8!6+O_0-NUN^;G_$/ _@(8%M"_%0,WR?QA\+KTA
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M,3 Y+FAT;5!+ 0(4 Q0    ( $:!:5=&P"@^" ,  (T)   1
M  "  1,5  !A=&AA+3(P,C,Q,3 Y+GAS9%!+ 0(4 Q0    ( $:!:5=^B+NI
M @8  $\V   5              "  4H8  !A=&AA+3(P,C,Q,3 Y7VQA8BYX
M;6Q02P$"% ,4    " !&@6E7C7]4L[,$  "4+   %0              @ %_
M'@  871H82TR,#(S,3$P.5]P<F4N>&UL4$L! A0#%     @ 1H%I5PVM=R+K
M)@  =4$"  \              ( !92,  &%T:&$M97@Y.5\Q+FAT;5!+!08
1    !0 % $$!  !]2@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
